Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | F12 | P00748 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350664 | 1.00 | PLAU (0.50) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL26462746 | 0.85 | PLAU (0.45) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL29956842 | 0.73 | PLG (0.31) | F12PLG | |
| SCHEMBL4434307 | 0.72 | CYP3A4 (0.44) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL58112 | 0.71 | PLAU (0.56) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL8869515 | 0.71 | PLAU (0.46) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL29923403 | 0.70 | PLAU (0.60) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL199273 | 0.70 | PLAU (0.60) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL14508372 | 0.70 | KDM4E (0.45) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL20787979 | 0.70 | PLAU (0.54) | PLAUCYP2A6F12NCF1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | CEPHALON LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250270252-A1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12325725-B2 | Cyclin-dependent kinase degraders and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| EP-3752517-B1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-3752518-B1 | CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2024-05-23 | — | — | US | disclosed |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | 89BIO LTD (IL) | 2024-01-23 | — | — | US | disclosed |
| US-20230365620-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4267584-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-11-01 | — | — | EP | disclosed |
| EP-4242196-A1 | METHOD FOR PREPARING DEUTERATED ANTHRACENE COMPOUND, REACTION COMPOSITION, DEUTERATED ANTHRACENE COMPOUND AND COMPOSITION | Lg Chem, Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
| EP-1708701-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2006-10-11 | — | — | EP | disclosed |
| US-6998408-B2 | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-02-14 | — | — | US | disclosed |
| US-20050182082-A1 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-18 | — | — | US | disclosed |
| WO-2005072732-A1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20030078255-A1 | 6-5, 6-6, or 6-7 Heterobicycles as factor xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-24 | — | — | US | disclosed |
| EP-0775115-B1 | DIMERIC ARYLISOQUINOLINE ALKALOIDS AND SYNTHESIS METHODS THEREOF | US HEALTH (US) | 2003-01-22 | — | — | EP | disclosed |
| US-5786482-A | Dimeric arylisoquinoline alkaloids and synthesis method thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-07-28 | — | — | US | disclosed |
| EP-0775115-A1 | DIMERIC ARYLISOQUINOLINE ALKALOIDS AND SYNTHESIS METHODS THEREOF | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5578729-A | Dimeric arylisoquinoline alkaloid compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996003381-A1 | DIMERIC ARYLISOQUINOLINE ALKALOIDS AND SYNTHESIS METHODS THEREOF | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078255-A1 | 6-5, 6-6, or 6-7 Heterobicycles as factor xa inhibitors | HABP2, SERPINC1, F7 | PLAU 39/4885CYP2A6 123/4885F12 4/4885 |
| US-20050182082-A1 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKB2, NR3C1 | PLAU 4719/4885CYP2A6 1164/4885F12 3371/4885 |
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | PLAU 4106/4885CYP2A6 165/4885F12 3925/4885 |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | FASN, CES1, FADS2 | PLAU 4106/4885CYP2A6 165/4885F12 3925/4885 |
| US-12325725-B2 | Cyclin-dependent kinase degraders and methods of use | CDK9, CDK19, CDK8 | PLAU 2707/4885CYP2A6 2577/4885F12 2662/4885 |
| US-20230365620-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF USE | CDK9, CDK19, CDK1 | PLAU 2125/4885CYP2A6 2312/4885F12 519/4885 |
| US-20250270252-A1 | CYCLIN-DEPENDENT KINASE DEGRADERS AND METHODS OF USE | CDK9, CDK19, CDK1 | PLAU 2493/4885CYP2A6 2755/4885F12 2839/4885 |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | PLAU 4106/4885CYP2A6 165/4885F12 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.